Molecular predictive testing in precision oncology: The Italian experience.
molecular cytopathology
molecular pathology
next-generation sequencing
precision medicine
target therapy
Journal
Cancer cytopathology
ISSN: 1934-6638
Titre abrégé: Cancer Cytopathol
Pays: United States
ID NLM: 101499453
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
10
03
2020
revised:
09
04
2020
accepted:
21
04
2020
entrez:
5
9
2020
pubmed:
5
9
2020
medline:
23
2
2021
Statut:
ppublish
Résumé
In this review, we describe molecular pathology testing to predict response to targeted treatment of solid tumors, focusing on Italian routine clinical practice. The combination of the universal health care system organized at national, regional, and local levels has led a decentralized model, with a large number of local laboratories performing in-house molecular testing following guidelines issued and external quality assessment organized by the Italian Society of Pathology and Cytopathology-Italian Division of the International Academy of Pathology. In this framework, in the early days of predictive testing, sponsored informatics platforms support to set up national programs that aimed to integrate the activity of oncologists and pathologists to test cancer patients for druggable alterations. More recently, reimbursement for molecular testing is being covered completely by the Italian National Health Service. In the near future, considering the development of complex technologies, we expect that outsourcing samples to next-generation sequencing referral laboratories will take place.
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
622-628Informations de copyright
© 2020 American Cancer Society.
Références
European Medicines Agency. Vectibix. Accessed March 3, 2020. https://www.ema.europa.eu/en/medicines/human/EPAR/vectibix
European Medicines Agency. Erbitux. Accessed March 3, 2020. https://www.ema.europa.eu/en/medicines/human/EPAR/erbitux
Hynes SO, Pang B, James JA, Maxwell P, Salto-Tellez M. Tissue-based next generation sequencing: application in a universal healthcare system. Br J Cancer. 2017;116:553-560.
Vozikis A, Cooper DN, Mitropoulou C, et al. E-mail policy statement test pricing and reimbursement in genomic medicine: towards a general strategy. Public Health Genomics. 2016;19:352-363.
Roy-Chowdhuri S, Pisapia P, Salto-Tellez M, et al. Invited review-next-generation sequencing: a modern tool in cytopathology. Virchows Archiv. 2019;475:3-11.
Nowak F, Calvo F, Soria J-C. Europe does it better: molecular testing across a national health care system-the French example. Am Soc Clin Oncol Educ B. 2013;33:332-337.
Normanno N, Pinto C, Castiglione F, et al. KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment. PLoS One. 2011;6:e29146.
Marchetti A, Normanno N, AIOM-SIAPEC-IAP, et al. Recommendations for mutational analysis of EGFR in lung carcinoma. Pathologica. 2010;102:119-126.
Marchetti A, Ardizzoni A, Papotti M, et al. Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer: a consensus of the italian association of medical oncology and the Italian society of pathology and cytopathology. J Thorac Oncol. 2013;8:352-358.
Normanno N, Pinto C, Castiglione F, et al. The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences. J Transl Med. 2015;13:287.
Normanno N, Pinto C, Taddei G, et al. Results of the first italian external quality assurance scheme for somatic EGFR mutation testing in non-small-cell lung cancer. J Thorac Oncol. 2013;8:773-778.
Normanno N, Fenizia F, Castiglione F, et al. External quality assessment for EGFR mutations in Italy: improvements in performances over the time. ESMO Open. 2017;2:e000160.
Marchetti A, Barberis M, Papotti M, et al. ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: results of the first italian external quality assurance scheme. J Thorac Oncol. 2014;9:1470-1476.
Barone C, Pinto C, Normanno N, et al. KRAS early testing: consensus initiative and cost-effectiveness evaluation for metastatic colorectal patients in an italian setting. PLoS One. 2014;9:e85897.
Vigliar E, Malapelle U, Bellevicine C, de Luca C, Troncone G. Outsourcing cytological samples to a referral laboratory for EGFR testing in non-small cell lung cancer: does theory meet practice? Cytopathology. 2015;26:312-317.
Associazione Italiana di Oncologia Medica. Libro Bianco della Oncologia Italiana-Centrioncologici. Accessed March 4, 2020. https://librobianco.aiom.it/
I.Stat. Popolazione residente al 1° gennaio. Accessed March 4, 2020. http://dati.istat.it/Index.aspx?DataSetCode=DCIS_POPRES1
Malapelle U, Pepe F, Pisapia P, et al. Harmonization of next generation sequencing procedure in Italian laboratories: a multi-institutional evaluation of the SiRe panel. Front Oncol. 2020:236.
Savic Prince S, Bubendorf L. Predictive potential and need for standardization of PD-L1 immunohistochemistry. Virchows Archiv. 2019;474:475-484.